Atomwise

1. Upload the structure of the target protein (e.g., amyloid-beta) to the Atomwise platform.

2. Screen millions of compounds against the target protein using the platform's AI-driven virtual screening capabilities.

3. Analyze the results to identify potential drug candidates with high binding affinity and favorable ADMET properties.

4. Validate the top candidates in vitro and in vivo.

5. Optimize the lead compounds for improved efficacy and safety.

1. Upload the structure of the target protein (e.g., a cancer-related protein) to the Atomwise platform.

2. Screen a library of existing drugs against the target protein using the platform's AI-driven virtual screening capabilities.

3. Analyze the results to identify potential drug candidates with high binding affinity and favorable ADMET properties.

4. Validate the top candidates in vitro and in vivo.

5. Conduct clinical trials to evaluate the efficacy and safety of the repurposed drug in cancer patients.

1. Upload the structure of the lead compound and the target protein to the Atomwise platform.

2. Use the platform's AI algorithms to identify modifications to the lead compound that improve its binding affinity, selectivity, and ADMET properties.

3. Synthesize and test the modified compounds in vitro and in vivo.

4. Select the optimized compound for further development.

1. Gather available data on the target protein or biological pathway involved in the rare disease.

2. Upload the data to the Atomwise platform.

3. Use the platform's AI algorithms to identify potential drug candidates based on the limited data available.

4. Validate the top candidates in vitro and in vivo.

5. Collaborate with patient advocacy groups and other stakeholders to accelerate the development of new treatments for the rare disease.

1. Upload the structures of the interacting proteins to the Atomwise platform.

2. Use the platform's AI algorithms to design novel molecules that disrupt the protein-protein interaction.

3. Synthesize and test the designed molecules in vitro and in vivo.

4. Optimize the lead compounds for improved efficacy and safety.

1. Utilize the platform's AI-driven virtual screening to quickly identify potential drug candidates that bind to key viral targets, such as the spike protein or viral protease.

2. Prioritize existing drugs for repurposing based on their predicted binding affinity and ADMET properties.

3. Collaborate with research institutions to rapidly validate the identified drug candidates in vitro and in vivo.

4. Share the results and data with the scientific community to accelerate the development of new COVID-19 treatments.